Prostate Cancer Surveillance Is Safe With Continued Monitoring

Video

Men with low-risk prostate cancer can usually safely forego treatment as long as they continue to monitor their disease with their clinicians, an expert said.

While patients with prostate cancer do not always need to undergo a biopsy, it is essential that they adhere to follow-up care with their providers, explained Dr. Eric Li, a urology resident at the Northwestern University Feinberg School of Medicine in Chicago.

In December 2021, active surveillance, which is when a patient is not treated but is monitored by their health care team, became the National Comprehensive Cancer Network (NCCN’s) preferred option for men with low-risk prostate cancer. More recently, at the 2023 American Urological Association’s 2023 conference, Li presented research on factors that may predict a patient’s need to undergo a repeat MRI and then biopsy.

Li and his team found that factors such as prostate-specific antigen (PSA) kinetics, which is the rate of PSA change over time, and prostate health index kinetics were predictive of the need for a repeat MRI or biopsy for patients who are undergoing active surveillance for their disease.

The study findings also showed that the rate of clinically significant prostate cancer — meaning disease that is aggressive and typically requires immediate treatment — was only 2%.

READ MORE: Long-Term Prostate Cancer Outcomes May Not Differ by Treatment Type

“So overall, it’s quite safe to monitor these patients, but we just need to make sure that they follow up,” Li said in an interview with CURE®’s sister publication, Urology Times®.

Transcript

If someone does not undergo a biopsy, one of the important things is that we still need to keep following them. So, they're not quite out of the woods yet. Actually, one of the projects that I'm presenting tomorrow looks at the patients who were not biopsied in this group and what happened to them over time. And we found that things like the PSA kinetics, as well as the prostate health index kinetics were predictive of undergoing a repeat MRI and then some of those patients also proceeded to biopsy.

But we actually found that the rate of subsequent cancer detection with almost two years of follow-up was low, at 2%. So overall, it's quite safe to monitor these patients, but we just need to make sure that they follow up.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey. If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key. “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained. READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Sue Friedman in an interview with CURE
Dr. Giles in an interview with CURE
Related Content
Image of a brain with a red dot symbolizing a tumor.

Dickey Betts Died, ‘Shopaholic’ Author Announces Cancer Diagnosis and More

April 19th 2024
Article

From the Allman Brothers Band’s singer Dickey Betts dying after a cancer diagnosis to the “Shopaholic” author announcing her glioblastoma diagnosis, here’s what is happening in the cancer space this week.

Read More

Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

January 30th 2024
Podcast

Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.

Listen

Image of a patient speaking with a doctor.

Orgovyx Manages Testosterone, Reduces Side Effects in Prostate Cancer

April 15th 2024
Article

Compared to other treatments, patients’ testosterone levels return to baseline levels faster following treatment with Orgovyx.

Read More

CURE Cancer Horizons podcast logo

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

January 29th 2024
Podcast

CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.

Listen

Image of a statue with its arms on its head, knees to its chest.

Getting Through Grief Caused By Cancer

April 8th 2024
Article

When experiencing loss, always look forward and have hope.

Read More

Dr. Jennifer Plichta in an interview with CURE

Genetic Testing for Breast Cancer May Benefit Family Members

March 12th 2024
Article

An expert explained that patients with breast cancer who undergo genetic testing may help their family members, regardless of whether patients have children.

Read More